Clinical TrialMay 21, 2026, 08:02 AM
Apyx Medical Publishes Positive Clinical Data for Cellulite Treatment
AI Summary
Apyx Medical announced the publication of new clinical data in Aesthetic Surgery Journal Open Forum, highlighting a promising approach to improving cellulite and skin laxity. The prospective investigator-initiated clinical study evaluated a combination treatment utilizing Avéli® for targeted subcision and Apyx's Renuvion® to reduce skin laxity. Results showed progressive improvement over time, with up to 81.8% of patients demonstrating improved cellulite appearance and increased levels of collagen and elastin observed in a subset through 180 days post-treatment.
Key Highlights
- Apyx Medical announced publication of new clinical data in Aesthetic Surgery Journal Open Forum.
- The study evaluated a combination treatment of Avéli® and Renuvion® for cellulite and skin laxity.
- Up to 81.8% of patients showed improvement in cellulite appearance at 180 days post-treatment.
- Objective 3D imaging demonstrated measurable reductions in dimple volume, surface area, and depth.
- Histological analysis in a subset of patients showed increased collagen and elastin through 180 days.
- The prospective investigator-initiated clinical study involved 22 patients.
- The findings support multi-modality approaches for cellulite and laxity.
- Renuvion® is part of Apyx Medical's Helium Plasma Platform Technology products.
Price Impact
More from APYX